ATE384700T1 - Tetrahydroisochinolin- und tetrahydrobenzazepin derivative als igf-1r inhibitoren - Google Patents

Tetrahydroisochinolin- und tetrahydrobenzazepin derivative als igf-1r inhibitoren

Info

Publication number
ATE384700T1
ATE384700T1 AT04719900T AT04719900T ATE384700T1 AT E384700 T1 ATE384700 T1 AT E384700T1 AT 04719900 T AT04719900 T AT 04719900T AT 04719900 T AT04719900 T AT 04719900T AT E384700 T1 ATE384700 T1 AT E384700T1
Authority
AT
Austria
Prior art keywords
tetrahydroisocinoline
igf
inhibitors
tetrahydrobenzazepine derivatives
tetrahydrobenzazepine
Prior art date
Application number
AT04719900T
Other languages
English (en)
Inventor
Jan Gunzinger
Kurt Leander
Original Assignee
Analytecon Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Analytecon Sa filed Critical Analytecon Sa
Application granted granted Critical
Publication of ATE384700T1 publication Critical patent/ATE384700T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT04719900T 2004-03-12 2004-03-12 Tetrahydroisochinolin- und tetrahydrobenzazepin derivative als igf-1r inhibitoren ATE384700T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CH2004/000147 WO2005087743A1 (en) 2004-03-12 2004-03-12 Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors

Publications (1)

Publication Number Publication Date
ATE384700T1 true ATE384700T1 (de) 2008-02-15

Family

ID=34957074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04719900T ATE384700T1 (de) 2004-03-12 2004-03-12 Tetrahydroisochinolin- und tetrahydrobenzazepin derivative als igf-1r inhibitoren

Country Status (21)

Country Link
US (1) US7875631B2 (de)
EP (1) EP1732898B1 (de)
JP (1) JP2007528877A (de)
CN (1) CN100590118C (de)
AR (1) AR049323A1 (de)
AT (1) ATE384700T1 (de)
AU (1) AU2004317166B2 (de)
BR (1) BRPI0418462A (de)
CA (1) CA2555745C (de)
DE (1) DE602004011578T2 (de)
DK (1) DK1732898T3 (de)
EA (1) EA200601687A1 (de)
ES (1) ES2299825T3 (de)
IL (1) IL177307A (de)
NO (1) NO20063794L (de)
PL (1) PL1732898T3 (de)
PT (1) PT1732898E (de)
SI (1) SI1732898T1 (de)
TW (1) TW200530213A (de)
WO (1) WO2005087743A1 (de)
ZA (1) ZA200607198B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364673T3 (es) * 2005-09-09 2011-09-12 Analytecon S.A. Isoquinolinas como inhibidores de igf-1r.
EP1940796A1 (de) * 2005-09-09 2008-07-09 Analytecon S.A. Isochinolinderivate als igf-1r-inhibitoren
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
EP2544672A1 (de) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Kombinations-antikrebstherapie
RU2013104506A (ru) * 2010-07-05 2014-08-10 Актелион Фармасьютиклз Лтд 1-фенилзамещенные производные гетероциклила и их применение в качестве модуляторов рецептора простагландина d2
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
ES2624379T3 (es) 2011-12-21 2017-07-14 Idorsia Pharmaceuticals Ltd Derivados de heterociclilo y su uso como moduladores del receptor de prostaglandina D2
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN104672136B (zh) * 2013-11-30 2017-01-25 沈阳药科大学 1‑取代菲基‑n‑烷基(酰基)‑6,7‑二甲氧基‑1,2,3,4‑四氢异喹啉衍生物及其制备方法和用途
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CN112500345B (zh) * 2020-12-18 2022-06-21 西安石油大学 α-氰基季碳取代四氢异喹啉化合物的合成方法
CN117776987A (zh) * 2022-09-27 2024-03-29 苏州阿尔脉生物科技有限公司 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349472A (en) 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
PH25651A (en) * 1986-05-21 1991-08-21 Duphar Int Res New di, tetrahydroisoquinoline derivatives
WO1990002119A1 (en) * 1988-08-18 1990-03-08 Banyu Pharmaceutical Co., Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
EP1113007A1 (de) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten
AU2002222853A1 (en) * 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic compounds
SE0102168D0 (sv) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor

Also Published As

Publication number Publication date
AU2004317166A1 (en) 2005-09-22
CA2555745A1 (en) 2005-09-22
DK1732898T3 (da) 2008-05-13
DE602004011578T2 (de) 2009-02-19
US20070129399A1 (en) 2007-06-07
EA200601687A1 (ru) 2007-04-27
CN100590118C (zh) 2010-02-17
TW200530213A (en) 2005-09-16
AU2004317166B2 (en) 2010-11-11
CA2555745C (en) 2011-05-31
AR049323A1 (es) 2006-07-19
PL1732898T3 (pl) 2008-06-30
DE602004011578D1 (de) 2008-03-13
CN1922147A (zh) 2007-02-28
BRPI0418462A (pt) 2007-06-05
IL177307A (en) 2011-09-27
PT1732898E (pt) 2008-04-07
ZA200607198B (en) 2008-04-30
IL177307A0 (en) 2006-12-10
ES2299825T3 (es) 2008-06-01
US7875631B2 (en) 2011-01-25
JP2007528877A (ja) 2007-10-18
EP1732898A1 (de) 2006-12-20
WO2005087743A1 (en) 2005-09-22
EP1732898B1 (de) 2008-01-23
NO20063794L (no) 2006-12-12
SI1732898T1 (sl) 2008-06-30

Similar Documents

Publication Publication Date Title
CY2022001I2 (el) Παραγωγα του uk-2a
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
ATE501138T1 (de) Thiophenderivate als chk-1-inhibitoren
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
DE602006011363D1 (de) Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
ATE527240T1 (de) Polyzyklische indazol-derivate als erk-hemmer
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE485268T1 (de) Pyrrolidin-derivate als erk-hemmer
ATE478064T1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ATE521607T1 (de) Piperidinderivate als renin-inhibitoren
ATE394399T1 (de) Tetrahydropyridoindolderivate
ATE540935T1 (de) Chinazolinderivate
ATE383361T1 (de) Pyrrazolopyrimidinderivate
ATE417830T1 (de) Sulfonylbenzimidazolderivate
ZA200607198B (en) Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate
ATE472532T1 (de) Oxindole als kinaseinhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1732898

Country of ref document: EP